Syndax Pharmaceuticals (SNDX) Equity Average (2016 - 2025)
Historic Equity Average for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Q3 2025 value amounting to $136.4 million.
- Syndax Pharmaceuticals' Equity Average fell 6592.6% to $136.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $136.4 million, marking a year-over-year decrease of 6592.6%. This contributed to the annual value of $421.2 million for FY2024, which is 1755.26% down from last year.
- Latest data reveals that Syndax Pharmaceuticals reported Equity Average of $136.4 million as of Q3 2025, which was down 6592.6% from $186.2 million recorded in Q2 2025.
- In the past 5 years, Syndax Pharmaceuticals' Equity Average registered a high of $523.0 million during Q1 2024, and its lowest value of $136.4 million during Q3 2025.
- For the 5-year period, Syndax Pharmaceuticals' Equity Average averaged around $341.0 million, with its median value being $368.2 million (2022).
- In the last 5 years, Syndax Pharmaceuticals' Equity Average skyrocketed by 46444.44% in 2021 and then plummeted by 6592.6% in 2025.
- Quarter analysis of 5 years shows Syndax Pharmaceuticals' Equity Average stood at $303.7 million in 2021, then soared by 32.63% to $402.8 million in 2022, then increased by 13.39% to $456.7 million in 2023, then fell by 28.34% to $327.3 million in 2024, then crashed by 58.31% to $136.4 million in 2025.
- Its Equity Average was $136.4 million in Q3 2025, compared to $186.2 million in Q2 2025 and $251.6 million in Q1 2025.